Cargando…

HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Hepatic arterial infusion chemotherapy (HAIC) and Transarterial chemoembolization (TACE) both showed good local efficacy in advanced or unresectable hepatocellular carcinoma (HCC). We performed a systematic review and meta-analysis to compare the effect of HAIC with TACE in patients with unresectabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Junguo, Zhang, Jinjuan, Wang, Yijun, Shu, Guiming, Lou, Cheng, Du, Zhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794325/ https://www.ncbi.nlm.nih.gov/pubmed/36595819 http://dx.doi.org/10.1097/MD.0000000000032390

Ejemplares similares

TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma
por: Huang, Dexiao, et al.
Publicado: (2017)

Combination therapy: Meta-analysis of the effects of TACE and cryoablation on hepatocellular carcinoma
por: Yuan-Dong, Sun, et al.
Publicado: (2019)

Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?
por: Ge, Naijian, et al.
Publicado: (2023)

TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study
por: Yuan, Yichuan, et al.
Publicado: (2023)

The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma
por: Tu, Jianfei, et al.
Publicado: (2016)

Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma
por: Jiang, Jiang, et al.
Publicado: (2017)

Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma
por: Jeong, Joonho, et al.
Publicado: (2021)

Dexamethasone prevents TACE-induced adverse events: A meta-analysis
por: Chang, Lei, et al.
Publicado: (2020)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma
por: Tsai, Wei-Lun, et al.
Publicado: (2020)

Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study
por: Tang, Chengwu, et al.
Publicado: (2016)

Trans-catheter arterial chemoembolization plus Sorafenib, an unsuccessful therapy in the treatment of hepatocellular carcinoma?: A systematic review and meta-analysis
por: Zhang, Tao, et al.
Publicado: (2020)

Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis
por: Du, Sihao, et al.
Publicado: (2023)

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Ren, Baosheng, et al.
Publicado: (2019)

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC
por: Yao, Wang, et al.
Publicado: (2023)

Radiofrequency ablation versus microwave ablation for early stage hepatocellular carcinoma: A PRISMA-compliant systematic review and meta-analysis
por: Han, Jie, et al.
Publicado: (2020)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Li, Mu-xing, et al.
Publicado: (2015)

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021)

Evaluation of plasma D-dimer for the diagnosis in Chinese patients with hepatocellular carcinoma: A meta-analysis
por: Fang, Ping, et al.
Publicado: (2020)

Relationship between digestive diseases and COVID-19 severity and mortality: A protocol for systematic review and meta-analysis
por: Li, Jinjuan, et al.
Publicado: (2020)

Radiofrequency Ablation Versus Surgical Resection for Small Unifocal Hepatocellular Carcinomas
por: Lei, J.Y., et al.
Publicado: (2014)

The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Pang, Qing, et al.
Publicado: (2015)

Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis
por: Zhang, XiuPing, et al.
Publicado: (2017)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis
por: Zhou, Jian-Ming, et al.
Publicado: (2021)

The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis
por: Wang, Yubin, et al.
Publicado: (2023)

Systematic Review and Meta-analysis of Endostar Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Hepatocellular Carcinoma
por: Zhang, Ya-Qing, et al.
Publicado: (2017)

Surgical outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma for various resection extent
por: Chen, Junhua, et al.
Publicado: (2017)

Risk factors of infection after transarterial chemoembolization for hepatocellular carcinoma: A protocol for systematic review and meta-analysis
por: Shi, Zhipeng, et al.
Publicado: (2021)

Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
por: Bi, Yonghua, et al.
Publicado: (2023)

Circulating MicroRNAs as Biomarkers in Hepatocellular Carcinoma Screening: A Validation Set From China
por: Jiang, Li, et al.
Publicado: (2015)

Metabolomic biomarkers for hepatocellular carcinoma: A systematic review
por: Feng, Ningning, et al.
Publicado: (2022)

Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis
por: Long, Guan-Bao, et al.
Publicado: (2020)

Comparative Efficacy of Interventional Therapies for Early-stage Hepatocellular Carcinoma: A PRISMA-compliant Systematic Review and Network Meta-analysis
por: Lan, Tian, et al.
Publicado: (2016)

Survival comparison between radiofrequency ablation and surgical resection for patients with small hepatocellular carcinoma: A systematic review and meta-analysis
por: Xuan, Dongchun, et al.
Publicado: (2021)

The association between pretreatment serum alkaline phosphatase and prognosis in hepatocellular carcinoma: A meta-analysis
por: Sun, Ping, et al.
Publicado: (2020)

Association of interleukin-6 gene polymorphisms with the risk of hepatocellular carcinoma: An up-to-date meta-analysis
por: An, Pei-Pei, et al.
Publicado: (2020)

Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma
por: Suh, Young Ju, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mo8ek7f0lheipgf34dgtou3u3l